Pyruvate analog

The concept is not limited to analogs of simple linear organophosphates (e.g. phosphoenol pyruvate analog as inhibitor of 5-enolpyruvylshikimate-3-phosphate (EPSP) synthase [71]) but can be extended to cyclic phosphates (e.g. cyclic phosphoinositol analog as a phospholipase C inhibitor [72]) and transition state analogs (e. g. purine nucleoside phosphorylase (PNP) inhibitor [73]) (Scheme 4.30). 

The strict specificity of PFL for pyruvate and formate as substrates places some restrictions on the structure of potential active site-directed inhibitors. Therefore, acetyl phosphinate (207) is a natural candidate for a PFL inhibitor, as it is not only a pyruvate analog, but is also a derivative of hypophosphite, a known mechanism-based PFL inactivator. In the absence of CoA, 100 mM acetyl phosphinate is an effective time-dependent inhibitor of PFL, although the inactivation reaction does not appear to be first order. If 55 mM CoA is included in the inactivation reaction mixture, first-order kinetics are now observed, and with 10 mM acetyl phosphinate the half-life of the inactivation reaction is 3 min. In the presence of 5 mM pyruvate (no CoA), PFL is completely protected from inactivation by 100 mM acetyl phosphinate. 

The method is quite effective, but is not widely used now because of the ubiquity of digital computers. Zuman and Patel - 36. show circuit designs for some kinetic schemes. Williams and Bruice made good use of the analog computer in their study of the reduction of pyruvate by 1,5-dihydroflavin. In this simulation eight rate constants were evaluated variations in these parameters of 5% yielded discemibly poorer curve fits. 

Substitution in position 4 displays a more complex influence. Cyclization of the 4-methyl- and 4-ethyl-thiosemicarbazones of phenylpyruvic acid and of the 4-methylthiosemicarbazone of phenyl-glyoxylic acid (103) was readily achieved (104), whereas it was not possible to cyclize the analogous 4-methyl derivatives of pyruvic and glyoxylic acids. It thus appears that cyclization is hindered by substitution in position 4 and that this unfavorable effect can be partly relieved by the known favorable effect of an aryl or aralkyl group in the a-position. 

The conversion occurs through a multistep sequence of reactions catalyzed by a complex of enzymes and cofactors called the pyruvate dehydrogenase complex. The process occurs in three stages, each catalyzed by one of the enzymes in the complex, as outlined in Figure 29.11 on page 1152. Acetyl CoA, the ultimate product, then acts as fuel for the final stage of catabolism, the citric acid cycle. All the steps have laboratory analogies. 

Step 1 of Figure 29.13 Carboxylation Gluconeogenesis begins with the carboxyl-afion of pyruvate to yield oxaloacetate. The reaction is catalyzed by pyruvate carboxylase and requires ATP, bicarbonate ion, and the coenzyme biotin, which acts as a carrier to transport CO2 to the enzyme active site. The mechanism is analogous to that of step 3 in fatty-acid biosynthesis (Figure 29.6), in which acetyl CoA is carboxylated to yield malonyl CoA. 

NeuA, has broad substrate specificity for aldoses while pyruvate was found to be irreplaceable. As a notable distinction, KdoA was also active on smaller acceptors such as glyceraldehyde. Preparative applications, for example, for the synthesis of KDO (enf-6) and its homologs or analogs (16)/(17), suffer from an unfavorable equilibrium constant of 13 in direction of synthesis [34]. The stereochemical course of aldol additions generally seems to adhere to a re-face attack on the aldehyde carbonyl, which is complementary to the stereoselectivity of NeuA. On the basis of the results published so far, it may be concluded that a (31 )-configuration is necessary (but not sufficient), and that stereochemical requirements at C-2 are less stringent [71]. 

The biosynthesis of Kdo and neuraminic acid is known to involve enol-pyruvate phosphate and D-arabinose or 2-acetamido-2-deoxy-D-mannose, respectively. Nothing is known about the biosynthesis of all the other glycu-losonic acids. One interesting problem is, for example, whether the two 5,7-diamino-3,5,7,9-tetradeoxynonulosonic acids are synthesized analogously to neuraminic acid, from a three- and a six-carbon fragment, by modification of neuraminic acid on the sugar nucleotide level, or by a third, less obvious route. 

Chiral Bronsted acid co-catalysts do not promote formation of optically enriched products in analogous couplings to pyruvates, although increased rate and conversion in response to the Bronsted acid co-catalyst is unmistakably apparent. For pyruvates, protonation likely occurs subsequent to the C-C... 

Na salts of ribonucleotide triphosphates (Roche or Sigma) bovine serum albumin RNase-free, 20 mg/ml (Roche) RNasin ribonuclease inhibitor, 40 U/ml (Promega) both bacteriophage T7 RNA polymerase and RNA Cap structure analog m7G(5/)ppp(5/)G are from BioLabs DNase-RNase-free (Roche) complete EDTA-free proteinase inhibitors cocktail (Roche) pyruvate kinase (PK) (Roche). 

In addition to the aforementioned allenic steroids, prostaglandins, amino acids and nucleoside analogs, a number of other functionalized allenes have been employed (albeit with limited success) in enzyme inhibition (Scheme 18.56) [154-159]. Thus, the 7-vinylidenecephalosporin 164 and related allenes did not show the expected activity as inhibitors of human leukocyte elastase, but a weak inhibition of porcine pancreas elastase [156], Similarly disappointing were the immunosuppressive activity of the allenic mycophenolic acid derivative 165 [157] and the inhibition of 12-lipoxygenase by the carboxylic acid 166 [158]. In contrast, the carboxyallenyl phosphate 167 turned out to be a potent inhibitor of phosphoenolpyruvate carboxylase and pyruvate kinase [159]. Hydrolysis of this allenic phosphate probably leads to 2-oxobut-3-enoate, which then undergoes an irreversible Michael addition with suitable nucleophilic side chains of the enzyme. 

---